Amgen's Repatha Recommended for Broader Use in Reducing Cardiovascular Risk
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation to broaden the indications for Amgen's Repatha. The recommendation supports its use in patients at risk of a first heart attack or stroke.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the approved uses for Amgen's drug Repatha. This recommendation supports the use of Repatha for patients with an elevated risk of experiencing a first heart attack or stroke.
The CHMP's assessment is based on clinical trial data demonstrating that Repatha (evolocumab) significantly reduced the risk of first heart attack or stroke in patients with established atherosclerotic cardiovascular disease. Repatha is a PCSK9 inhibitor that lowers LDL cholesterol.
According to Amgen, Repatha is the first and only PCSK9 inhibitor to show a significant reduction in the risk of adjudicated cardiovascular events like heart attack and stroke in primary prevention trials. This expanded indication could allow more patients to benefit from the drug's protective effects.
The CHMP's positive opinion is a step towards regulatory approval by the European Commission and may establish new standards for managing cardiovascular risk.